Cognition Therapeutics’ (CGTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report released on Monday, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, July 30th. B. Riley restated a “neutral” rating and set a $1.00 price target (down from $5.00) on shares of Cognition Therapeutics in a research report on Tuesday, August 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Cognition Therapeutics Stock Up 2.4 %

CGTX opened at $0.50 on Monday. The company’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $1.27. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The stock has a market cap of $20.06 million, a price-to-earnings ratio of -0.53 and a beta of 1.34.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. During the same period in the prior year, the firm earned ($0.16) earnings per share. As a group, sell-side analysts anticipate that Cognition Therapeutics will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. AWM Investment Company Inc. purchased a new stake in shares of Cognition Therapeutics in the first quarter worth $1,183,000. Hohimer Wealth Management LLC bought a new stake in Cognition Therapeutics during the 1st quarter valued at about $410,000. CM Management LLC raised its holdings in Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the last quarter. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its holdings in shares of Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares during the last quarter. 43.35% of the stock is owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.